--Honor recognizes excellence in ChIP, DNA methylation innovation and service--
SAN DIEGO, Oct. 23 /PRNewswire/ -- Genpathway, Inc. announced today that the company has received the 2008 Frost & Sullivan North American Services in Drug Discovery Technologies Healthcare Innovation Award.
The award recognizes Genpathway for providing superior services for chromatin immunoprecipitation (ChIP) and DNA methylation assays that directly contribute to discoveries in gene regulation, epigenetics, and gene transcription.
"Frost & Sullivan recognizes Genpathway for its outstanding efforts to provide researchers an efficient and economical solution to fast-track notoriously difficult ChIP procedures," explained Frost & Sullivan industry analyst Christianne Bird. "As the recognized experts in ChIP, Genpathway consistently is the first to deliver cutting-edge technologies to the market and teams with top technology providers to offer the newest ChIP techniques available. For its commitment to providing innovative services to advance life sciences research and drug discovery and its position as the leader in its field, Frost & Sullivan is pleased to present Genpathway the 2008 North America Services in Drug Discovery Technologies Healthcare Innovation Award."
"Genpathway is honored to be recognized with this prestigious award from Frost & Sullivan," said Mary Harper, PhD, Chief Scientific Officer of Genpathway. "As interest in and demand for ChIP and DNA methylation assays continues to expand rapidly, our goal is to provide researchers across a broad range of disease areas and research fields a fast-track to discovery using our whole-genome assays. Genpathway's complete ChIP and DNA IP solutions are proving highly valuable for understanding gene regulation and genetic pathways by studying transcription factor binding, gene transcription, and epigenetic events such as DNA methylation and histone modifications."
Frost & Sullivan presents its
Copyright©2008 PR Newswire.
All rights reserved